Assignee
GENMAB BV
NL·7 granted patents·22 pending applications·22 citations·filing 2013–2024
Top patents by PatentIndex Score
29 records- 0197US12049512B2Antibody variants and uses thereofGENMAB BV·Filed 2020·Granted Jul 30, 2024·5 cites·17 claims
- 0291US11180572B2Dimeric protein with triple mutationsGENMAB BV·Filed 2013·Granted Nov 23, 2021·12 cites·45 claims
- 0390US10882913B2Anti-DR5 antibodies and methods of use thereofGENMAB BV·Filed 2019·Granted Jan 5, 2021·4 cites·23 claims
- 0485US2025223374A1Antibody variants and uses thereofGENMAB BV·Filed 2024·Application pending·0 cites
- 0576US2025145720A1Human igg1 fc region variants and uses thereofGENMAB BV·Filed 2024·Application pending·0 cites
- 0676US2022411522A1Anti-death receptor antibodies and methods of use thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 0775US12173076B2Polypeptide variants and uses thereofGENMAB BV·Filed 2018·Granted Dec 24, 2024·1 cites·15 claims
- 0874US2024141057A1Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereofGENMAB BV·Filed 2023·Application pending·0 cites
- 0973US12247080B2Anti-DR5 antibodies and methods of use thereofGENMAB BV·Filed 2020·Granted Mar 11, 2025·0 cites·15 claims
- 1073US2025326854A1Polypeptide variants and uses thereofGENMAB BV·Filed 2024·Application pending·0 cites
- 1173US2023212301A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 1272US2023109496A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 1366US2023107363A1Polypeptide variants and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 1464US2022332801A1Antibodies and methods of use thereof in treatment of infectious diseaseGENMAB BV·Filed 2021·Application pending·0 cites
- 1561US2019202926A1Anti-death receptor antibodies and methods of use thereofGENMAB BV·Filed 2016·Application pending·0 cites
- 1661US2019144554A1Anti-dr5 antibodies and methods of use thereofGENMAB BV·Filed 2016·Application pending·0 cites
- 1760US2020332016A1Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereofGENMAB BV·Filed 2020·Application pending·0 cites
- 1853US10647774B2Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereofGENMAB BV·Filed 2017·Granted May 12, 2020·0 cites·9 claims
- 1953US2023293680A1A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myelomaGENMAB BV·Filed 2021·Application pending·0 cites
- 2052US2015353636A1Human igg1 fc region variants and uses thereofGENMAB BV·Filed 2013·Application pending·0 cites
- 2151US2021230301A1Dimeric protein with triple mutationsGENMAB BV·Filed 2020·Application pending·0 cites
- 2250US2020123237A1Antibodies and methods of use thereof in treatment of infectious diseaseGENMAB BV·Filed 2017·Application pending·0 cites
- 2349US12338289B2Antibody variant combinations and uses thereofGENMAB BV·Filed 2019·Granted Jun 24, 2025·0 cites·17 claims
- 2448US2022411529A1Antibody variant combinations and uses thereofGENMAB BV·Filed 2020·Application pending·0 cites
- 2548US2022315661A1Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancerGENMAB BV·Filed 2020·Application pending·0 cites
- 2648US2023089196A1Methods for the quantification of glycoproteinsGENMAB BV·Filed 2021·Application pending·0 cites
- 2747US2019276549A1Polypeptide variants and uses thereofGENMAB BV·Filed 2017·Application pending·0 cites
- 2844US2021107988A1Polypeptide variants and uses thereofGENMAB BV·Filed 2019·Application pending·0 cites
- 2929US2020247897A1Therapeutic antibodies based on mutated igg hexamersGENMAB BV·Filed 2018·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →